Cisplatin these drug are mostly used in the initial lung cancer treatment. Efficiency of this drug in combination with other drugs is being explored by a few of scientist these past few years. In year 2008, United States Food and Drug Administration (FDA) approved the combination of cisplatin and alimta as a first line lung cancer treatment. In combination with other drug that against of advance non small cell lung cancer especially maligant pleural mesothelioma.
In year 2007, based on Journal of National Cancer Institute has stated that cisplatin has more effective response rate than carboplatin in the advance non small cell lung cancer treatment. Carboplatin is a form lung cancer chemotherapy agent and used for treatment many types of cancer especially ovarian and non small cell lung cancer. Another similar finding from Science Daily, in year 2008. Andrea Ardizzoni, M.D., of University Hospital in Parma, Italy, he and his colleague conducted a review of nine randomized trials comparing the survival of 2,968 non small cell lung cancer patients who received either cisplatin or carboplatin, finding showed that patients who under treatment with cisplatin lived longer than those treated with carboplatin.
These results suggest that cisplatin produces slightly better response rates than carboplatin and may also improve survival in some patients.
